Objective  To evaluate the surgical outcomes of neoadjuvant chemoimmunotherapy for sleeve lobectomy. Methods  The clinical data of patients diagnosed as non-small-cell-lung-cancer (NSCLC) and evaluated to undergo sleeve lobectomy surgery at TianJin Chest Hospital were retrospectively analyzed. Patients were divided into two groups: a neoadjuvant treatment group and a surgery alone group. The clinical characteristics, perioperative parameters, and postoperative outcomes of two groups were compared. Results  Finally 22 patients were collected, including 19 males and 3 females with a median age of 63 years. There were 7 patients in the neoadjuvant treatment group, and 15 patients in the surgery alone group. There was no statistical difference in surgical time, intraoperative bleeding, lymph node dissection, postoperative catheterization time, and postoperative drainage volume between the two groups (P>0.05). In the neoadjuvant treatment group, 1 patient had a second thoracotomy exploration for hemostasis due to bronchial artery bleeding, 2 patients had wound infection, 1 patient had immune-associated pneumonia before surgery, and 1 patient had immune-associated pneumonia before postoperative adjuvant therapy. In the the neoadjuvant treatment group, 1/7 (14.3%) patients had a pathological complete response, and 3/7 (42.9%) patients achieved a major pathological response. Conclusion  The surgical difficulty and post-surgical complication rate of sleeve lobectomy with neoadjuvant chemoimmunotherapy are higher than those of surgery alone but also offer appropriate oncological outcomes. Overall, neoadjuvant chemo-immunotherapy sleeve lobectomy can be considered as a treatment option for patients with locally advanced lung cancer.